Literature DB >> 18197882

Role of calcitonin gene-related peptide and substance P in different models of pain.

R Greco1, C Tassorelli, G Sandrini, P Di Bella, S Buscone, G Nappi.   

Abstract

Calcitonin gene-related peptide (CGRP) and substance P (SP) play an important role in the development of pain and hyperalgesia. Experimental models have demonstrated that nitroglycerin (NTG)--a nitric oxide donor--provokes a hyperalgesic state, probably via the activation of second-order neurons in the nucleus trigeminalis caudalis. In order to gain further insight into the role of CGRP and SP in different types of experimental pain, we evaluated and compared changes in immunoreactivity (-ir) for these two neuropeptides at different levels of the central nervous system [nucleus trigeminalis caudalis (NTC) and dorsal horns of the lumbar spinal cord] in two animal models of hyperalgesia: systemic NTG administration and formalin test. Following NTG administration, CGRP-ir decreased steadily in the NTC, whereas SP-ir increased transiently. In the lumbar dorsal horns, NTG induced a decrease in SP-ir 1 h after its administration. Formalin injection induced an ipsilateral increase in both CGRP and SP immunostaining at 1 and 2 h in the lumbar dorsal horns. In the NTC, a significant decrease in CGRP-ir was observed at 1 h. The changes in the staining intensities were paralleled by changes in the numbers of CGRP and of SP varicosities in both the NTC and the lumbar dorsal horns. These findings show specific changes in CGRP and SP at different levels of the central nervous system in the different models of pain. In the case of the formalin test, the changes involve both neuropeptides synchronously and to the same extent, whereas in the case of NTG administration, CGRP seems to play a more prevalent and long-lasting role, particularly at the NTC level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18197882     DOI: 10.1111/j.1468-2982.2007.01468.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  22 in total

Review 1.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

2.  Diverse effects of Brilliant Blue G administration in models of trigeminal activation in the rat.

Authors:  Zsuzsanna Bohár; Gábor Nagy-Grócz; Annamária Fejes-Szabó; Lilla Tar; Anna M László; Alexandra Büki; Nikolett Szabadi; Veronika Vraukó; László Vécsei; Árpád Párdutz
Journal:  J Neural Transm (Vienna)       Date:  2015-08-23       Impact factor: 3.575

3.  Keratinocyte expression of calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanisms.

Authors:  Quanzhi Hou; Travis Barr; Lucy Gee; Jeff Vickers; James Wymer; Elisa Borsani; Luigi Rodella; Spiro Getsios; Trisha Burdo; Elan Eisenberg; Udayan Guha; Robert Lavker; John Kessler; Sridar Chittur; Dennis Fiorino; Frank Rice; Phillip Albrecht
Journal:  Pain       Date:  2011-06-17       Impact factor: 6.961

4.  Activation of spinal mu- and delta-opioid receptors potently inhibits substance P release induced by peripheral noxious stimuli.

Authors:  Hélène Beaudry; Dave Dubois; Louis Gendron
Journal:  J Neurosci       Date:  2011-09-14       Impact factor: 6.167

5.  Chemical sympathectomy increases susceptibility to ocular herpes simplex virus type 1 infection.

Authors:  Amanda Templeton; Gabrielle Nguyen; John D Ash; Rainer H Straub; Daniel J J Carr
Journal:  J Neuroimmunol       Date:  2008-05-20       Impact factor: 3.478

6.  Novel Therapeutic Targets in Neuroinflammation and Neuropathic Pain.

Authors:  Geeta Ramesh
Journal:  Inflamm Cell Signal       Date:  2014

7.  A sensory subpopulation depends on vesicular glutamate transporter 2 for mechanical pain, and together with substance P, inflammatory pain.

Authors:  Malin C Lagerström; Katarzyna Rogoz; Bjarke Abrahamsen; Anne-Li Lind; Caroline Olund; Casey Smith; José Alfredo Mendez; Åsa Wallén-Mackenzie; John N Wood; Klas Kullander
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-17       Impact factor: 11.205

8.  Effects of anandamide in migraine: data from an animal model.

Authors:  Rosaria Greco; Antonina Stefania Mangione; Giorgio Sandrini; Mauro Maccarrone; Giuseppe Nappi; Cristina Tassorelli
Journal:  J Headache Pain       Date:  2011-02-18       Impact factor: 7.277

Review 9.  Dural Immune Cells, CGRP, and Migraine.

Authors:  Louis K Balcziak; Andrew F Russo
Journal:  Front Neurol       Date:  2022-03-31       Impact factor: 4.086

10.  Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model.

Authors:  Rosaria Greco; Antonina Stefania Mangione; Giorgio Sandrini; Giuseppe Nappi; Cristina Tassorelli
Journal:  J Headache Pain       Date:  2014-03-17       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.